In fact, pharmacological antagonism of CXCR2 produced neuroprotective effects in different animal models of neurodegenerative diseases, including Alzheimer’s, by attenuating chemokine receptor expression in microglia, inhibiting receptor-mediated inflammatory reactivity and enhancing neuronal viability (Marsh and Flemming 2011; Ryu et al. 2015; Gorio et al. 2007). Here, CXCR2 is linked to neurodegenerative disease.